CN101416991A - Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof - Google Patents
Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof Download PDFInfo
- Publication number
- CN101416991A CN101416991A CNA2008101833661A CN200810183366A CN101416991A CN 101416991 A CN101416991 A CN 101416991A CN A2008101833661 A CNA2008101833661 A CN A2008101833661A CN 200810183366 A CN200810183366 A CN 200810183366A CN 101416991 A CN101416991 A CN 101416991A
- Authority
- CN
- China
- Prior art keywords
- preparation
- extract
- hirudo
- chinese medicine
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases, which is characterized in that the preparation is made from the following raw materials by the following weight ratio: red ginseng: panax notoginseng: hirudo: borneol equals to 1:0.3-3:0.1-3:0.01-0.05. The invention also discloses a method for preparing the dropping pill of the traditional Chinese medicine preparation. The preparation has the functions of supplementing qi, activating blood circulation, dredging collaterals, relieving pain, absorbing clots, removing suppository and the like, is clinically used for treating coronary heart disease, angina, cerebral arteriosclerosis, hyperlipidemia, cerebral thrombosis, cerebral apoplexy sequela, and the like, and characterized by fast dissolvent out and taking effect quickly with high efficacy.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, relate in particular to a kind of Chinese medicine preparation and preparation technology thereof who treats cardiovascular and cerebrovascular disease.
Background technology
Cardiovascular and cerebrovascular disease is meant because the general designation of ischemic or hemorrhage takes place in heart, brain and the body tissue that hyperlipemia, blood are sticky, atherosclerosis, hypertension etc. are caused, and is the No.1 dead disease that threatens human health and life maximum.World Health Organization (WHO) gave a warning in 1969, if do not control the fashion trend of coronary heart disease (CHD), coronary heart disease will become " human maximum epidemic diseases ", thereby medical circle is being sought prevention and treatment efficient ways and means to this type of disease always for a long time.Aspect endo-medicine, still the medicine that lacks better efficacy both at home and abroad, and fully show from a large amount of clinical treatments and animal experiment study, Chinese medicine effect aspect the control cardiovascular and cerebrovascular disease is remarkable, especially preventing and treating hyperlipemia, reduce sickness rate such as coronary heart disease, cerebral infarction, improve the heart, cerebral blood supply, reducing cardiovascular and cerebrovascular disease case fatality rate aspect has remarkable advantages.Developed at present as active drugs such as " SUXIAO JIUXIN WAN ", " FUFANG DANSHEN DIWAN ", " DIAOXINXUE KANG ", and obtained good curative effect.But clinical employed most Chinese medicines are taken problems such as having side effect is many, curative effect reduction for a long time based on causing resuscitation with aromatic drugs, blood circulation promoting and blood stasis dispelling.
Summary of the invention
Technical problem to be solved by this invention provides the Chinese medicine preparation of a kind of quick stripping, rapid-action, treatment cardiovascular and cerebrovascular disease that curative effect is high.
Another technical problem to be solved by this invention provides a kind of preparation technology of Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease of easy suitability for industrialized production.
For addressing the above problem, a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease of the present invention is characterized in that: said preparation is to be made by the raw material of following weight ratio: Radix Ginseng Rubra: Radix Notoginseng: Hirudo: Borneolum Syntheticum=1:0.3～3:0.1～3:0.01～0.05.
The said preparation dosage form is a drop pill.
The every ball of said preparation contains medicine extract 25～50mg, substrate 50～75mg.
The said preparation dosage form is tablet, granule, oral liquid, concentrated pill or capsule.
A kind of preparation technology of Chinese medicine preparation of aforesaid treatment cardiovascular and cerebrovascular disease, it may further comprise the steps:
(1) extract of preparation Radix Ginseng Rubra, Radix Notoginseng: at first respectively Radix Ginseng Rubra, Radix Notoginseng powder are broken into coarse powder, the water that adds 6～20 times of Radix Ginseng Rubra and three seven weight again, through heating extraction to relative density is 1.1～1.4, adding ethanol to pure mass concentration then is 50%～90%, leave standstill the back under the room temperature supernatant is reclaimed ethanol, be concentrated into thick extractum at last and get final product;
(2) extract of preparation Hirudo: Hirudo powder is broken into coarse powder, adds the ethanol of 6～15 times of Hirudo weight, mass concentration 40%～95%, through reflux, extract,, decompression recycling ethanol is concentrated into thick extractum at last and gets final product to there not being the alcohol flavor;
(3) extract and the Borneolum Syntheticum mix homogeneously with Radix Ginseng Rubra, Radix Notoginseng, Hirudo gets the drop pill extract;
(4) pharmaceutical base is heated to whole fusions, presses 30～100% of pharmaceutical base weight again and add the drop pill extract, move to the airtight and insulation under 65～90 ℃ of liquid containing bottle after stirring;
(5) under heat-retaining condition step (4) products therefrom is gone in the coolant by dropping-pill machine, condensation cured becomes ball;
(6) with the drop pill of molding through centrifugal removal coolant, and with drop pill screen, air-dry, polishing back packing gets final product.
Radix Ginseng Rubra, Radix Notoginseng extract in the described step (1) are at first respectively Radix Ginseng Rubra, Radix Notoginseng powder to be broken into coarse powder, the ethanol that adds 6～15 times of Radix Ginseng Rubra and three seven weight, concentration 60%～95% again, through reflux, extract,, filter after, decompression recycling ethanol is concentrated at last that thick extractum obtains.
Hirudo extract in the described step (2) is at first Hirudo powder to be broken into coarse powder, adds the hot water of 4～15 times of Hirudo weight, temperature≤70 ℃ again, reduce pressure then decocting liquid; Last collecting decoction, after filtration, concentrate the back spray drying and get final product.
Hirudo extract in the described step (2) is at first Hirudo powder to be broken into coarse powder, adds the sodium chloride of 6～15 times of Hirudo weight, mass concentration 0.9%, through seepage extract effusion; Again effusion is evaporated to 1/10～1/3 of original liquid amount under 60～80 ℃, dialyses, be concentrated into thick extractum then and get final product.
Pharmaceutical base in the described step (3) be in Polyethylene Glycol, poloxamer, glycerin gelatine, the polyoxyethylene monostearate any one or two or more.
Pharmaceutical base in the described step (3) also has interfacial agent polysorbate or dimethyl sulfoxide.
Coolant in the described step (5) is any one in liquid paraffin, dimethicone, the vegetable oil.
Said preparation adopts pharmaceutical coating material to make the coated dosage form of sugar-coat or film-coat.
Described coating material be in gelatin, arabic gum, Lac, zein, hydroxypropyl emthylcellulose, ethyl cellulose, polyacrylic resin, polyethylene acetal diethylamine ethyl ester, phthalic acid hydroxypropyl methylcellulose ester, polyvinyl acetate phthalic acid ester, the succinum acetic acid hydroxypropyl methylcellulose any one or two or more.
Radix Notoginseng sweet and slightly bitter taste among the side of the present invention, warm in nature, return liver stomach warp, have good hemostasia effect, significant hemopoietic function, can tighten and improve the arteria coronaria microcirculation, have the effect of immunomodulator, antitumor, blood fat reducing and cholesterol, but while the liver protecting, its removing stasis to stop bleeding, promoting blood circulation and stopping pain, promoting tissue regeneration by removing blood stasis is a monarch drug; The Radix Ginseng Rubra sweet and slightly bitter taste, warm in nature, return spleen lung heart channel, can be used for weak body and prostration, the cold extremities faint pulse, QI failing to control blood, metrostaxis, heart failure, cardiogenic shock, its strongly invigorating primordial QI, benefiting qi and supporting yang, but the YIN nourishing and the production of body fluid promoting of holding concurrently is a ministerial drug; The monarch and his subjects match, and tonifying QI to promote blood circulation brings out the best in each other; Hirudo salty in the mouth hardship, property is flat, and is poisonous, promoting blood circulation to remove obstruction in the collateral, dissipating blood stasis to promote menstruationg is thought assistant; Borneolum Syntheticum acrid in the mouth hardship is slightly cold, GUIXIN spleen lung meridian, its awakening consciousness, the refreshment of having one's ideas straightened out, clearing away heat to alleviate pain.All medicines share, and play the effect of activating qi and collateral, removing obstruction in the collateral to relieve pain, blood stasis dispelling embolism extinguishing altogether, reach reinforcement and elimination in combination, the purpose of giving consideration to both the incidental and fundamental.
Function cures mainly: benefiting QI for activating blood circulation, and removing obstruction in the collateral to relieve pain, blood stasis dispelling embolism extinguishing function is used for the treatment of coronary heart disease, angina pectoris, cerebral arteriosclerosis, hyperlipemia, cerebral thrombosis clinically, and apoplexy sequela etc. belong to blood stagnancy due to deficiency of QI, venation block person.
Usage and dosage: with the drop pill is example, oral or containing, one time 5～10 ball, 2～3 times on the one.
The present invention compared with prior art has the following advantages:
1, fast stripping: get the present invention's seven trematodiasis heart disease treating drop pills and carry out external dissolution experiment, in simulated gastric fluid, seven trematodiasis heart disease treating drop pills all molten loosing in the dissolution average out to 20%, 10 minute in the time of the 2nd minute.
2, pharmacodynamic experiment:
(1) the present invention's seven trematodiasis heart disease treating drop pills are to the influence of rats with myocardial ischemia due to coronary artery ligation and pituitrin, the isoproterenol:
Table 1: acute myocardial ischemia rat ECG ST section (mv) due to the pituitrin is raised the dynamic change influence
Annotate: compare with model group:
*P＜0.05,
*P＜0.01.
Table 2: to acute myocardial ischemia rat ECG ST section (mv) dynamic change influence due to the isoproterenol
Annotate: compare with model group:
*P＜0.05,
*P＜0.01.
Table 3: to the influence of acute myocardial ischemia rat blood serum SOD, MDA due to the pituitrin
Annotate: compare with the blank group
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model group.
Table 4: acute myocardial ischemia rat blood serum phosphoric acid due to the pituitrin is swashed the influence that sour enzyme (CK), lactic acid dehydrogenase (LDH) change
Annotate: compare with the blank group
*△ P＜0.05, △ △ P＜0.01 are compared with model group in P＜0.01.
Table 5: to acute myocardial ischemia rat plasma thromboxane (TXB due to the pituitrin
2), the influence that changes of prostaglandin (6-KeTo-PGFl α)
Annotate: compare with the blank group
*△ P＜0.05, △ △ P＜0.01 are compared with model group in P＜0.01.
Table 6: each organizes the variation of serum NO levels
| Group | n | NO(μmol/L) |
| Blank group | 7 | 20.85±6.52 |
| Model group | 6 | 7.26±2.10 * |
| Positive controls | 7 | 20.25±5.40# |
| The medicine low dose group | 5 | 22.60±5.54# |
| Dosage group in the medicine | 6 | 23.00±6.69# |
| The medicine high dose group | 6 | 28.48±7.59#▲ |
Annotate: compare with the blank group
*P＜0.01; Compare #P＜0.01 with model group; Compare with positive group ▲ P＜0.05.
Table 7: each organizes the variation of blood plasma ET content
| Group | n | ET(pg/ml) |
| Blank group | 7 | 133.90±20.72 |
| Model group | 6 | 164.67±21.67 * |
| Positive controls | 7 | 129.21±11.71## |
| The medicine low dose group | 5 | 131.46±17.25## |
| Dosage group in the medicine | 6 | 136.77±21.63# |
| The medicine high dose group | 6 | 125.17±20.14## |
Annotate: compare with the blank group
*P＜0.01; Compare #P＜0.05 with model group, ##P＜0.01.
Table 8: each organizes the variation of TNF-alpha content in the cardiac muscular tissue
| Group | n | TNF-α(ng/ml) |
| Blank group | 7 | 0.3929±0.0829 |
| Model group | 6 | 0.4848±0.0830 * |
| Positive controls | 7 | 0.4314±0.0713 |
| The medicine low dose group | 5 | 0.4586±0.1068 |
| Dosage group in the medicine | 6 | 0.4140±0.0426 |
| The medicine high dose group | 6 | 0.3430±0.0502#▲ |
Annotate: compare with the blank group
*P＜0.05; Compare #P＜0.01 with model group; Compare with positive group ▲ P＜0.05.
Table 9: each organizes the variation of IL-6 content in the cardiac muscular tissue
| Group | n | IL-6(pg/ml) |
| Blank group | 7 | 74.52±15.31 |
| Model group | 6 | 99.88±16.78 * |
| Positive controls | 7 | 80.11±13.76# |
| The medicine low dose group | 5 | 89.03±18.25 |
| Dosage group in the medicine | 6 | 86.37±17.94 |
| The medicine high dose group | 6 | 78.57±17.94# |
Annotate: compare with the blank group
*P＜0.01; Compare #P＜0.05 with model group
As can be seen, the present invention's seven trematodiasis heart disease treating drop pills can significantly improve the electrocardiogram of rats with myocardial ischemia from table 1～2.
As can be seen, the present invention's seven trematodiasis heart disease treating drop pills can significantly reduce cerebral ischemia re-pouring rat whole blood viscosity, blood plasma viscosity and packed cell volume, improve erythrocyte aggregation from table 3～9; Superoxide dismutase S OD in the serum, nitric oxide (NO) and blood plasma (6-Keto-PGF can significantly raise
1 α) level, reduce serum paraoxonase creatine phosphate kinase (CK), lactic acid dehydrogenase (LDH), malonaldehyde (MDA) and blood plasma thromboxance B
2(TXB
2), Endothelin (ET) content, reduce cardiac muscular tissue's tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) content.
(2) the antagonism experimental cerebral ischemia reperfusion injury rat model of the present invention's seven trematodiasis heart disease treating drop pills experiment:
Modelling: 70 of SD healthy rats, male and female half and half, body weight 200～220g, fasting is 12 hours before the operation.During operation at first the chloral hydrate with mass concentration 10% by 400mg/kg rat is carried out intraperitoneal injection of anesthesia, it is fixing then rat to be lain on the back, get the cervical region median incision, passivity is separated common carotid artery, folder closes bilateral common carotid arteries simultaneously, cause brain completeness ischemia, open bulldog clamp behind the 30min and pour into formation focal brain ischemia-reperfusion injury MODEL C IRI again; Secondly, injection cefalexin 0.2ml/200g, sew up wound; At last, control anus temperature is at 37.0 ± 1 ℃, and fasting is prohibited water and begun gastric infusion after 24 hours, until till when drawing materials after 7 days.
Table 10: to the influence of CIRI rat model whole blood viscosity, blood plasma viscosity (X ± s, n=8)
Annotate: compare with sham operated rats:
★P＜0.05,
★ ★P＜0.01; Compare with model group:
*P＜0.05,
*P＜0.01.
Table 11: to the influence of CIRI rat model erythrocyte rigidity index, aggregate index, deformation index (X ± s, n=8)
| Group | n | Rigidity index | Aggregate index | Deformation index |
| Sham operated rats | 10 | 4.62±1.16 | 2.96±0.26 | 0.62±0.11 |
| Model group | 10 | 9.62±1.23 ★ | 3.03±0.12 ★ | 0.49±0.08 ★ |
| Positive group | 10 | 3.93±1.09 | 2.87±0.24 | 0.71±0.14 |
| The medicine high dose group | 10 | 4.46±1.22 ** | 2.31±0.09 **△ | 0.64±0.12 **△ |
| Dosage group in the medicine | 10 | 6.23±1.19 ** | 2.53±0.14 **△ | 0.68±0.12 ** |
| The medicine low dose group | 10 | 7.85±1.14 * | 2.86±0.17 * | 0.69±0.19 ** |
Annotate: compare with sham operated rats:
★P＜0.01; Compare with model group:
*P＜0.05,
*P＜0.01; Compare with positive group:
△P＜0.05.
Table 12: to the influence of CIRI rat model packed cell volume, erythrocyte sedimentation rate (X ± s, n=8)
| Group | n | Erythrocyte sedimentation rate (MM/H) | Packed cell volume (%) |
| Sham operated rats | 10 | 3.16±1.24 | 47.65±3.21 |
| Model group | 10 | 4.68±1.80 ★ | 53.26±3.63 ★ |
| Positive group | 10 | 3.21±0.14 | 49.20±3.22 |
| The medicine high dose group | 10 | 3.01±0.12 *△ | 43.37±3.12 *△ |
| Dosage group in the medicine | 10 | 2.34±0.09 *△△ | 45.32±3.51 *△ |
| The medicine low dose group | 10 | 3.72±1.20 * | 46.84±3.42 *△ |
Annotate: compare with sham operated rats:
★P＜0.01; Compare with model group:
*P＜0.01; Compare with positive group:
△P＜0.05,
△ △P＜0.01.
Table 13: to rat CIRI cerebral tissue NO, blood plasma ET, TXB
2Variable effect (x ± s, n=10)
| Group | Number of animals | NO(μmol/L) | ET(ng/L) | TXB 2(ng/L) |
| The blank group | 10 | 42.1±12.2 | 375.5±42.2 | 391.4±35.6 |
| Sham operated rats | 10 | 41.9±16.3 | 377.6±49.5 | 391.8±116.6 |
| Model group | 10 | 40.0±15.4 ★ | 425.3±32.4 ★★ | 438.3±128.2 ★★ |
| Positive controls | 10 | 64.2±9.94 ** | 382.4±67.6 ** | 405.4±16.1 ** |
| The medicine high dose group | 10 | 67.6±17.0 ** | 385.5±45.6 ** | 398.9±128.8 ** |
| Dosage group in the medicine | 10 | 59.4±12.3 ** | 392.3±41.4 ** | 410.3±92.8 ** |
| The medicine low dose group | 10 | 48.2±21.0 ** | 408.5±20.3 * | 429.4±106.3 * |
Annotate: compare with sham operated rats:
★P＜0.05,
★ ★P＜0.01; Compare with model group:
*P＜0.05,
*P＜0.01.
As can be seen, the present invention's seven trematodiasis heart disease treating drop pills can significantly resist nitric oxide (NO) level, Endothelin (ET), thromboxance B in experimental cerebral ischemia reperfusion injury rat model blood plasma and the cerebral tissue from table 10～13
2(TXB
2) variation of content.
3, clinical experiment: adopt the present invention's seven trematodiasis heart disease treating drop pills treatment coronary heart disease, angina pectoris 50 examples, 4 weeks were 1 course of treatment, compare with matched group BUCHANG NAOXINTONG JIAONANG 36 examples, the result shows that curative effect to treat angina pectoris total effective rate, traditional Chinese medical science disease curative effect total effective rate, the ECG curative effect total effective rate of treatment group are respectively 93.67%, 92.70%, 68.83%, with the equal significance of matched group comparing difference (P＜0.05).
The specific embodiment
Embodiment 1 seven trematodiasis heart disease treating drop pills
(1) raw material: Radix Ginseng Rubra 250g, Radix Notoginseng 750g, Hirudo 750g, Borneolum Syntheticum 12.5g.
(2) extract of preparation Radix Ginseng Rubra, Radix Notoginseng: at first respectively Radix Ginseng Rubra, Radix Notoginseng are pulverized unit with the 30B type dust suction of the special drying equipment company limited of Changzhou Gray production and be ground into coarse powder, put into JD-SM type multi-function extractor that the safe company limited in three former U.S. Lechangs, Shaanxi is produced after crossing 10 mesh sieves, the water that adds 6～20 times of Radix Ginseng Rubra and three seven weight, 90～100 ℃ of following heating extraction 2～4 times, each 1～3 hour, get extracting solution; The cottonseed cake pressure filter that extracting solution is produced by last Asterias amurensis Lutken Wei Hui industry filter plant company limited filters again, behind the merging filtrate, it is 1.1～1.4 that the RNLG01-SM type multi-functional Chinese medicine liquid concentration pan that adopts the safe company limited in three former U.S. Lechangs, Shaanxi to produce is concentrated into relative density, adding ethanol then is 50%～90% to containing the alcohol amount, leave standstill under the room temperature after 12～36 hours supernatant is reclaimed ethanol to there not being the alcohol flavor, get final product with multi-functional Chinese medicine liquid concentration pan concentrated supernatant to thick extractum at last;
(3) extract of preparation Hirudo: Hirudo is pulverized unit with the 30B type dust suction of the special drying equipment company limited of Changzhou Gray production be ground into coarse powder, put into multi-function extractor after crossing 10 mesh sieves, the ethanol that adds 6～15 times of Hirudo weight, concentration 40%～95%, the JD that the safe company limiteies in three former U.S. Lechangs are produced through Shaanxi-SM type multi-function extractor reflux, extract, 2～4 times, each 1～3 hour, get extracting solution; After then extracting solution being filtered with the cottonseed cake pressure filter, T-SM type alcohol distillation column decompression recycling ethanol that the safe company limited in three former U.S. Lechangs is produced through Shaanxi gets final product with multi-functional Chinese medicine liquid concentration pan concentrated supernatant to thick extractum at last to there not being the alcohol flavor.
(4) with extract and the Borneolum Syntheticum mix homogeneously in the CH-200 type trough type mixing machine that the special drying equipment company limited of Changzhou Gray is produced of Radix Ginseng Rubra, Radix Notoginseng, Hirudo, get the drop pill extract.
(5) pharmaceutical base 750g Macrogol 4000,750g polyethylene glycol 6000 are added 1500g drop pill extract after being heated to whole fusions under 60～90 ℃, it is airtight to move to the CG1000 type insulation fluid reservoir that Guangzhou Haizhu District Nan Feng machinery plant produces after the JB type rustless steel agitator of putting into the mechanical company limited production of the Central-South medicine in Shanghai then stirs with 50～80 rev/mins speed, and 65～90 ℃ of insulations down.
(6) under heat-retaining condition the product in the step (5) is gone in the coolant dimethicone by the DWJ-2000S type dropping-pill machine that Yintai Kangdaer Pharmaceutical Co., Ltd produces, condensation cured becomes 3000 balls, and wherein every ball contains medicine extract 50mg, substrate 50mg.
(7) the centrifugal removal dimethicone of DWJJL-2000 type collection ball centrifuge that the drop pill of molding is produced through Yintai Kangdaer Pharmaceutical Co., Ltd, and the collection drop pill, again by the DWJSG-2000 type screening drying machine that Yintai Kangdaer Pharmaceutical Co., Ltd produces screen, air-dry, polishing back packing gets final product.
Embodiment 2 seven trematodiasis heart disease treating drop pills
(1) raw material: Radix Ginseng Rubra 250g, Radix Notoginseng 250g, Hirudo 250g, Borneolum Syntheticum 6.25g.
(2) extract of preparation Radix Ginseng Rubra, Radix Notoginseng: at first respectively Radix Ginseng Rubra, Radix Notoginseng are pulverized unit with dust suction and be ground into coarse powder, put into multi-function extractor after crossing 10 mesh sieves, the ethanol that adds 6～15 times of Radix Ginseng Rubra and three seven weight, concentration 60%～95% again, through multi-function extractor reflux, extract, 2～4 times, each 1～3 hour, get extracting solution; Then extracting solution is filtered by using the cottonseed cake pressure filter, behind the merging filtrate, adopt the alcohol distillation column decompression recycling ethanol, get final product with multi-functional Chinese medicine liquid concentration pan concentrated supernatant to thick extractum at last to there not being pure flavor.
(3) extract of preparation Hirudo: Hirudo is pulverized unit with dust suction be ground into coarse powder, put into multi-function extractor after crossing 10 mesh sieves, add the hot water of 4～15 times of Hirudo weight, temperature≤70 ℃, extract 2 times through the multi-function extractor decompression, each 1.5 hours, get decocting liquid; After decocting liquid filtered with the cottonseed cake pressure filter,, again the concentrated solution LPG type Highspeedcentrifugingandsprayingdrier spray drying that burnt Lu Si river produces through the Nan Zha south of a town, Jiangyin City is got final product with multi-functional Chinese medicine liquid concentration pan concentrated filtrate.
(4) acquisition of drop pill extract is with embodiment 1.
(5) pharmaceutical base 700g polyethylene glycol 6000 is added 500g drop pill extract after being heated to whole fusions under 60～90 ℃, add the 50g polyoxyethylene sorbitan monoleate again, put into then that to move to the insulation fluid reservoir after the rustless steel agitator stirs with 50～80 rev/mins speed airtight, and 65～90 ℃ of insulations down.
(6) under heat-retaining condition the product in the step (5) is gone in the coolant dimethicone by dropping-pill machine, condensation cured becomes 12500 balls, and wherein every ball contains medicine extract 40mg, substrate 60mg.
(7) with the drop pill of molding through the centrifugal removal dimethicone of collection ball centrifuge, and collect drop pill, again by the screening drying machine screen, air-dry, polishing back packing gets final product.
Embodiment 3 seven trematodiasis heart disease treating drop pills
(1) raw material: Radix Ginseng Rubra 250g, Radix Notoginseng 75g, Hirudo 25g, Borneolum Syntheticum 2.5g.
(2) extract of preparation Radix Ginseng Rubra, Radix Notoginseng is with embodiment 1 or embodiment 2.
(3) extract of preparation Hirudo: Hirudo is pulverized unit with dust suction be ground into coarse powder, put into multi-function extractor after crossing 10 mesh sieves, add the sodium chloride of 6～15 times of Hirudo weight, concentration 0.9%, extract 2～4 times through the multi-function extractor seepage, each 1～3 hour, get effusion; Again effusion is evaporated to 1/10～1/3 of original liquid amount with multi-functional Chinese medicine liquid concentration pan down at 60～80 ℃, be 0.003 micron ultrafilter membrane then with the aperture, operating pressure is that 1.0～7.0bar carries out getting dialysis solution behind the dialysis desalting, gets final product with multi-functional Chinese medicine liquid concentration pan concentrate dialysate to thick extractum at last.
(4) acquisition of drop pill extract is with embodiment 1.
(5) pharmaceutical base 590g Macrogol 4000 is added 300g drop pill extract after being heated to whole fusions under 60～90 ℃, add the 10g dimethyl sulfoxide again, put into then that to move to the insulation fluid reservoir after the rustless steel agitator stirs with 50～80 rev/mins speed airtight, and 65～90 ℃ of insulations down.
(6) under heat-retaining condition the product in the step (5) is gone in the coolant dimethicone by dropping-pill machine, condensation cured becomes 9000 balls, and wherein every ball contains medicine extract 33mg, substrate 67mg.
(7) with the drop pill of molding through the centrifugal removal dimethicone of collection ball centrifuge, and collect drop pill, again by the screening drying machine screen, air-dry, polishing back packing gets final product.
Embodiment 4 seven trematodiasis heart disease treating drop pills
(1) raw material: Radix Ginseng Rubra 250g, Radix Notoginseng 83g, Hirudo 83g, Borneolum Syntheticum 6g.
(2) extract of preparation Radix Ginseng Rubra, Radix Notoginseng is with embodiment 1 or embodiment 2.
(3) extract of preparation Hirudo is with embodiment 1, embodiment 2 or embodiment 3.
(4) acquisition of drop pill extract is with embodiment 1.
(5) pharmaceutical base 450g polyethylene glycol 6000,450g poloxamer 188 (Poloxamer188) are added 300g drop pill extract after being heated to whole fusions under 60～90 ℃, put into then that to move to the insulation fluid reservoir after the rustless steel agitator stirs with 50～80 rev/mins speed airtight, and 65～90 ℃ of insulations down.
(6) under heat-retaining condition the product in the step (5) is gone in the coolant vegetable oil by dropping-pill machine, condensation cured becomes 12000 balls, and wherein every ball contains medicine extract 25mg, substrate 75mg.
(7) with the drop pill of molding through the centrifugal removal vegetable oil of collection ball centrifuge, and collect drop pill, again by the screening drying machine screen, air-dry, polishing back packing gets final product.
Embodiment 5 seven trematodiasis heart disease treating drop pills
(1) raw material: Radix Ginseng Rubra 250g, Radix Notoginseng 750g, Hirudo 500g, Borneolum Syntheticum 7.5g.
(2) extract of preparation Radix Ginseng Rubra, Radix Notoginseng is with embodiment 1 or embodiment 2.
(3) extract of preparation Hirudo is with embodiment 1, embodiment 2 or embodiment 3.
(4) acquisition of drop pill extract is with embodiment 1.
(5) pharmaceutical base 800g Poloxamer 188 is added 400g drop pill extract after being heated to whole fusions under 60～90 ℃, put into then that to move to the insulation fluid reservoir after the rustless steel agitator stirs with 50～80 rev/mins speed airtight, and 65～90 ℃ of insulations down.
(6) under heat-retaining condition the product in the step (5) is gone in the aqueous paraffin of coolant by dropping-pill machine, condensation cured becomes 12000 balls, and wherein every ball contains medicine extract 33mg, substrate 67mg.
(7) with the drop pill of molding through the centrifugal removal liquid Paraffin of collection ball centrifuge, and collect drop pill, again by the screening drying machine screen, air-dry, polishing back packing gets final product.
Embodiment 6 seven trematodiasis heart disease treating drop pills
(1) raw material: Radix Ginseng Rubra 250g, Radix Notoginseng 125g, Hirudo 125g, Borneolum Syntheticum 10g.
(2) extract of preparation Radix Ginseng Rubra, Radix Notoginseng is with embodiment 1 or embodiment 2.
(3) extract of preparation Hirudo is with embodiment 1, embodiment 2 or embodiment 3.
(4) acquisition of drop pill extract is with embodiment 1.
(5) pharmaceutical base 600g glycerin gelatine, 200g polyoxyethylene monostearate are added 400g drop pill extract after being heated to whole fusions under 60～90 ℃, put into then that to move to the insulation fluid reservoir after the rustless steel agitator stirs with 50～80 rev/mins speed airtight, and 65～90 ℃ of insulations down.
(6) under heat-retaining condition the product in the step (5) is gone in the aqueous paraffin of coolant by dropping-pill machine, condensation cured becomes 12000 balls, and wherein every ball contains medicine extract 33mg, substrate 67mg.
(7) with the drop pill of molding through the centrifugal removal liquid Paraffin of collection ball centrifuge, and collect drop pill, again by the screening drying machine screen, air-dry, polishing back packing gets final product.
Claims (10)
1, a kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease is characterized in that: said preparation is to be made by the raw material of following weight ratio: Radix Ginseng Rubra: Radix Notoginseng: Hirudo: Borneolum Syntheticum=1:0.3～3:0.1～3:0.01～0.05.
2, the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 1 is characterized in that: the said preparation dosage form is a drop pill.
3, the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 2 is characterized in that: the every ball of said preparation contains medicine extract 25～50mg, substrate 50～75mg.
4, the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 1 is characterized in that: the said preparation dosage form is tablet, granule, oral liquid, concentrated pill or capsule.
5, a kind of preparation technology of the Chinese medicine preparation as claim 2 or 3 described treatment cardiovascular and cerebrovascular diseases, it may further comprise the steps:
(1) extract of preparation Radix Ginseng Rubra, Radix Notoginseng: at first respectively Radix Ginseng Rubra, Radix Notoginseng powder are broken into coarse powder, the water that adds 6～20 times of Radix Ginseng Rubra and three seven weight again, through heating extraction to relative density is 1.1～1.4, adding ethanol to pure mass concentration then is 50%～90%, leave standstill the back under the room temperature supernatant is reclaimed ethanol, be concentrated into thick extractum at last and get final product;
(2) extract of preparation Hirudo: Hirudo powder is broken into coarse powder, adds the ethanol of 6～15 times of Hirudo weight, mass concentration 40%～95%, through reflux, extract,, decompression recycling ethanol is concentrated into thick extractum at last and gets final product to there not being the alcohol flavor;
(3) extract and the Borneolum Syntheticum mix homogeneously with Radix Ginseng Rubra, Radix Notoginseng, Hirudo gets the drop pill extract;
(4) pharmaceutical base is heated to whole fusions, presses 30～100% of pharmaceutical base weight again and add the drop pill extract, move to the airtight and insulation under 65～90 ℃ of liquid containing bottle after stirring;
(5) under heat-retaining condition step (4) products therefrom is gone in the coolant by dropping-pill machine, condensation cured becomes ball;
(6) with the drop pill of molding through centrifugal removal coolant, and with drop pill screen, air-dry, polishing back packing gets final product.
6, the preparation technology of the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 5, it is characterized in that: Radix Ginseng Rubra, Radix Notoginseng extract in the described step (1) are at first respectively Radix Ginseng Rubra, Radix Notoginseng powder to be broken into coarse powder, the ethanol that adds 6～15 times of Radix Ginseng Rubra and three seven weight, concentration 60%～95% again, after reflux, extract,, filtration, decompression recycling ethanol is concentrated at last that thick extractum obtains.
7, the preparation technology of the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 5, it is characterized in that: the Hirudo extract in the described step (2) is at first Hirudo powder to be broken into coarse powder, the hot water that adds 4～15 times of Hirudo weight, temperature≤70 ℃ again, reduce pressure then decocting liquid; Last collecting decoction, after filtration, concentrate the back spray drying and get final product.
8, the preparation technology of the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 5, it is characterized in that: the Hirudo extract in the described step (2) is at first Hirudo powder to be broken into coarse powder, the sodium chloride that adds 6～15 times of Hirudo weight, mass concentration 0.9%, through seepage extract effusion; Again effusion is evaporated to 1/10～1/3 of original liquid amount under 60～80 ℃, dialyses, be concentrated into thick extractum then and get final product.
9, the preparation technology of the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 5 is characterized in that: the pharmaceutical base in the described step (3) be in Polyethylene Glycol, poloxamer, glycerin gelatine, the polyoxyethylene monostearate any one or two or more.
10, the preparation technology of the Chinese medicine preparation of treatment cardiovascular and cerebrovascular disease as claimed in claim 5 is characterized in that: the pharmaceutical base in the described step (3) also has interfacial agent polysorbate or dimethyl sulfoxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101833661A CN101416991B (en) | 2008-11-29 | 2008-11-29 | Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101833661A CN101416991B (en) | 2008-11-29 | 2008-11-29 | Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101416991A true CN101416991A (en) | 2009-04-29 |
| CN101416991B CN101416991B (en) | 2011-01-26 |
Family
ID=40628117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101833661A Active CN101416991B (en) | 2008-11-29 | 2008-11-29 | Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101416991B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104826071A (en) * | 2015-05-25 | 2015-08-12 | 苗怡文 | Traditional Chinese medicine preparation for treating cerebral hemorrhage sequelae and preparation method of traditional Chinese medicine preparation |
| CN105998247A (en) * | 2016-06-17 | 2016-10-12 | 齐齐哈尔市第医院 | Traditional Chinese medicine for treating carotid plaque |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1140066A (en) * | 1995-07-07 | 1997-01-15 | 广州白云山制药总厂 | Formula of and producing method for "Maitongling" oral preparation for promoting blood circulation |
| CN1288748A (en) * | 1999-09-17 | 2001-03-28 | 郅永谦 | Medicine for treating cardiac and cerebral vascular diseases and its preparation |
| CN101168042A (en) * | 2007-11-07 | 2008-04-30 | 周鲁菲 | Traditional Chinese medicine preparation for curing cardiovascular and cerebrovascular diseases and preparing method |
-
2008
- 2008-11-29 CN CN2008101833661A patent/CN101416991B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104826071A (en) * | 2015-05-25 | 2015-08-12 | 苗怡文 | Traditional Chinese medicine preparation for treating cerebral hemorrhage sequelae and preparation method of traditional Chinese medicine preparation |
| CN105998247A (en) * | 2016-06-17 | 2016-10-12 | 齐齐哈尔市第医院 | Traditional Chinese medicine for treating carotid plaque |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101416991B (en) | 2011-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396543B (en) | Pure traditional Chinese medicine preparation for treating cardio-cerebrovascular disease | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102068682A (en) | Chinese medicinal composition for treating digestive system diseases and preparation method thereof | |
| CN102626468A (en) | Traditional Chinese medicine combination for treating hepatitis B and preparing method and application thereof | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN101416991B (en) | Traditional Chinese medicine preparation for treating cerebrovascular disease and preparation technique thereof | |
| CN101884661A (en) | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases | |
| CN101167789B (en) | Tumor recovering capsule and production method thereof | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN100355434C (en) | Medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN100500189C (en) | Medicament for treating ulcerative colitis and preparation process thereof | |
| CN1244372C (en) | Chinese medicinal preparation for treating cardiac blood vessel disease and its preparation method | |
| CN114558058B (en) | Traditional Chinese medicine composition for treating vascular dementia and preparation thereof | |
| CN101167796B (en) | Monascus and red sage root composition for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN103405724B (en) | A kind of Chinese medicine composition and preparation method thereof | |
| CN101612304A (en) | A kind of compound Chinese medicinal preparation and preparation method for the treatment of coronary heart disease and cerebral blood supply insufficiency | |
| CN1097454C (en) | Weight-lossing essence for human body | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
| CN100375632C (en) | Extractive from combined vegetable drug for treating heart disease of coronary sclerosis, and method of extraction | |
| CN105169090B (en) | A kind of gastrodia tuber eucommia compound medicament composition | |
| CN104800686A (en) | Medicine composition for treating overeating sequelae and preparation method and purpose of medicine composition | |
| CN1314429C (en) | Chinese traditional medicine for treating cardiac arrhythmia and its preparation method | |
| CN105477397A (en) | Traditional Chinese medicine soft capsule for foot bath | |
| CN1099290C (en) | Chinese medicine and its prescription for promoting blood circulation and reducing blood fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180131 Address after: 730314 Gansu, Lanzhou, New District, Kunlun Mountains Avenue, No. 2299, No. Patentee after: Lanzhou heshengtang herbal health products Innovation Research Institute Co.,Ltd. Address before: 730000 Dingxi East Road, Chengguan District, Gansu, China, No. 35, No. Patentee before: Wu Hongyan |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230323 Address after: 730314 No. 2299 middle section of Kunlun Mountains Avenue, Lanzhou New District, Lanzhou, Gansu. Patentee after: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Address before: 730314 No. 2299 middle section of Kunlun Mountains Avenue, Lanzhou New District, Lanzhou, Gansu. Patentee before: Lanzhou heshengtang herbal health products Innovation Research Institute Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Traditional Chinese medicine preparations and their preparation techniques for treating cardiovascular and cerebrovascular diseases Effective date of registration: 20230907 Granted publication date: 20110126 Pledgee: Lanzhou New Area Sub Branch of China Everbright Bank Co.,Ltd. Pledgor: LANZHOU HOLYSHINE PHARMACEUTICAL CO.,LTD. Registration number: Y2023980055831 |